

# Update for Achondroplasia Associations

## Vosoritide status around the world

Vosoritide is a C-type natriuretic peptide (CNP) analog that has been approved for use in several countries as of July 1, 2022. Specifics of vosoritide's approval and accessibility will vary by country.

This will be the final clinical development program update for vosoritide in achondroplasia. For additional information regarding vosoritide or ongoing clinical data, please consult with a medical professional.

To date, 251 children with achondroplasia from eight countries have been enrolled in seven BioMarin clinical studies evaluating the safety and efficacy of vosoritide. These children and their families have been crucial to the ongoing research of vosoritide. We are grateful to everyone who participates in our clinical studies.

July 2022



### For additional information:

- For information and resources about living with achondroplasia, please visit [www.achondroplasia.com](http://www.achondroplasia.com)
- For inquiries or to provide feedback from advocacy organizations, please contact [patientadvocacy@bmrn.com](mailto:patientadvocacy@bmrn.com)
- Contact BioMarin Medical Information toll free at 1-800-983-4587 or [medinfo@bmrn.com](mailto:medinfo@bmrn.com)